** TD Cowen initiates coverage of U.S.-listed shares of Centessa Pharmaceuticals 260y.F, CNTA.O with "buy" rating
** Brokerage says co's experimental drug, ORX750, is "best-in-class" for treating excessive daytime sleepiness (EDS)
** EDS is a condition where a person feels very sleepy during the day, even after getting enough sleep at night
** Notes ORX750 "restored wakefulness at low doses with clean safety" in early-stage trial
** Brokerage says ORX750 demonstrated "higher potency and OX2R selectivity" compared with competitors in early development
** OX2R, also known as orexin receptor 2, is a protein in the brain that helps control sleep and wakefulness
** All 9 brokerages rate stock "buy" or higher; their median PT is $27 - LSEG data
** Stock more than doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.